Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › aflibercept

aflibercept

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of aflibercept

64 trials tracked of aflibercept: 40 in phase 3 or 4 and 22 with published results. The most-cited published study has 777 citations.

64Trials tracked
40Phase 3 & 4
0Recruiting
22With published results
Phase distribution
Phase 4 10 Phase 3 30 Phase 2 23 Other / NA 1
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA) Completed · 777 cited
  2. Phase 4 Aflibercept in Polypoidal Choroidal Vasculopathy Completed · 275 cited
  3. Phase 4 Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration Completed · 256 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) Completed · 227 cited
  5. Phase 3 Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Completed · 215 cited
  6. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE) Completed · 175 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema Completed · 175 cited
  2. Phase 3 Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease Completed · 135 cited
  3. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed · 113 cited
  4. Phase 3 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion Completed · 91 cited
  5. Phase 4 Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept Completed · 74 cited
  6. Phase 3 Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed · 42 cited
  7. Phase 4 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed · 39 cited
  8. Phase 4 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO Completed · 37 cited
  9. Phase 4 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed · 31 cited
  10. Phase 4 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Completed · 21 cited
  11. Phase 3 Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) Completed · 18 cited
  12. Phase 3 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Completed · 16 cited
  13. Phase 3 Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement Completed · 15 cited
  14. Phase 3 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied Completed · 15 cited
  15. Phase 3 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Completed · 4 cited
  16. Phase 3 A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] Completed
  17. Phase 4 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed
  18. Phase 4 Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD Completed
  19. Phase 4 A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema Completed
  20. Phase 3 Colorectal Cancer Metastatic Completed
  21. Phase 3 Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  22. Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity Completed
  23. Phase 3 A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) Completed
  24. Phase 3 A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  25. Phase 3 A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) Completed
  26. Phase 3 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Completed
  27. Phase 3 To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema Completed
  28. Phase 3 A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) Completed
  29. Phase 3 A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Completed
  30. Phase 3 VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration) Completed
  31. Phase 3 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer Completed
  32. Phase 3 Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen Completed
  33. Phase 3 Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed
  34. Phase 3 A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy Completed
  35. Phase 2 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) Completed
  36. Phase 2 A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration Completed
  37. Phase 2 Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy Completed
  38. Phase 2 A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD Completed
  39. Phase 2 A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema Completed
  40. Phase 2 VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer Completed
  41. Phase 2 AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites Completed
  42. Phase 2 A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD Completed
  43. Phase 2 Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy Completed
  44. Phase 2 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer Completed

Showing the 50 most-cited and recently-updated of 64 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Biosimilar anti-VEGF agents show comparable visual outcomes and safety to reference anti-VEGF agents
Ophthalmology Meta-analysis
Biosimilar anti-VEGF agents show comparable visual outcomes and safety to reference anti-VEGF agents Biosimilar drugs show similar results for several retinal diseases
This systematic review and meta-analysis evaluates biosimilar anti-VEGF agents compared to reference products for several retinal diseases. …
New data shows that biosimilar drugs perform as well as brand name drugs for patients with several types of vision-threatening eye condition…
Oct 4, 2026
Faricimab 6 mg every sixteen weeks outperforms aflibercept and ranibizumab in ARMD visual acuity
Ophthalmology Meta-analysis
Faricimab 6 mg every sixteen weeks outperforms aflibercept and ranibizumab in ARMD visual acuity Faricimab shows better vision outcomes for age related macular degeneration
This meta-analysis of 8 studies involving 8458 study populations found that faricimab 6 mg every sixteen weeks showed superior effects on be…
A new treatment option for age related macular degeneration may offer better vision and thinner retinal tissue than current standard drugs.
Aug 4, 2026
Aflibercept 8 mg at extended intervals yields comparable outcomes to 2 mg regardless of severity
Ophthalmology RCT
Aflibercept 8 mg at extended intervals yields comparable outcomes to 2 mg regardless of severity Higher doses of aflibercept show similar results for macular degeneration
This post hoc descriptive subgroup analysis of a randomized controlled trial involving 869 treatment-naže patients with neovascular age-rela…
A higher dose of aflibercept may offer the same vision benefits as lower doses for patients with neovascular age-related macular degeneratio…
Jul 5, 2026
Fluocinolone Acetonide Implant Shows Reduced Injection Frequency for Diabetic Macular Edema
Ophthalmology RCT
Fluocinolone Acetonide Implant Shows Reduced Injection Frequency for Diabetic Macular Edema Fluocinolone Acetonide Implant May Reduce Injection Frequency for DME
A Phase 4 trial shows fluocinolone acetonide implants achieve similar visual outcomes to aflibercept with significantly fewer total injectio…
A new eye implant for diabetic macular edema may significantly reduce the number of monthly injections needed to maintain vision.
Jul 5, 2026
Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan
Orthopedics & Sports Medicine Guideline
Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan Jordan Eye Drug Biosimilar Slashes Costs and Boosts Patient Access
This budget impact analysis from a Jordanian public sector perspective estimates that switching from aflibercept to ranibizumab's biosimilar…
Switching to a biosimilar version of a common eye drug could save Jordan’s public health system millions and help more patients get treatmen…
Frontiers May 8, 2026
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
Ophthalmology FDA Approval
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR FDA approves Pavblu to treat several eye conditions that cause vision loss.
The FDA approved Pavblu (aflibercept) for neovascular AMD, macular edema following RVO, DME, and DR. It is a VEGF inhibitor administered by …
The FDA approved Pavblu (aflibercept) for wet age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopa…
FDA May 5, 2026
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME
Ophthalmology Meta-analysis
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME Aflibercept biosimilars match the original drug for eye disease treatment
This systematic review and meta-analysis evaluated aflibercept biosimilars versus reference aflibercept for neovascular age-related macular …
A large review of 4064 patients found that aflibercept biosimilars work just as well as the original drug for two common eye conditions.
May 1, 2026
Aflibercept 8 mg extended dosing maintains visual gains with fewer injections versus 2 mg every 8 weeks in DME
Ophthalmology RCT
Aflibercept 8 mg extended dosing maintains visual gains with fewer injections versus 2 mg every 8 weeks in DME Aflibercept 8 mg every 16 weeks matches standard dosing for diabetic macular edema
This randomized, double-masked, noninferiority phase 2/3 trial enrolled 658 patients aged ≥ 18 years with center-involved diabetic macular e…
A new trial shows that aflibercept 8 mg every 16 weeks works as well as the standard 2 mg every 8 weeks for diabetic macular edema with fewe…
May 1, 2026
Post hoc analysis compares brolucizumab and aflibercept for diabetic macular edema
Ophthalmology RCT
Post hoc analysis compares brolucizumab and aflibercept for diabetic macular edema A New Eye Injection Works Even If You've Had Treatment Before
A post hoc analysis of a randomized trial in 517 participants with diabetic macular edema compared intravitreal brolucizumab to aflibercept …
People with diabetic eye disease who have already tried other injections may still get meaningful vision improvement from brolucizumab.
Apr 14, 2026
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Oncology Meta-analysis
PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
Frontiers Apr 9, 2026
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
Ophthalmology FDA Approval
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO FDA approves a new, higher-dose version of the eye medicine Eylea
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
FDA Apr 7, 2026
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Ophthalmology Meta-analysis
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Apr 2, 2026

All aflibercept Articles